Advertise on podcast: DarshanTalks Podcast

Send us Fan Mail  In this episode of the KLF Deep Dive, Darshan Kulkarni deconstructs a persistent and dangerous myth circulating in life sciences and investment circles: the Private Membership Association (PMA). While often marketed as a "contract-based loophole" to evade FDA oversight and civil liability, the reality in federal court is starkly different. Darshan examines the constitutional limits of "freedom of association" and analyzes key case law—including Little v. Q Lasers—to demonstrate why PMAs are viewed by judges as red flags rather than legal shields. If you are advising clients on regulatory shortcuts, this is a must-listen briefing on maintaining professional integrity and statutory compliance.  Support the show www.kulkarnilawfirm.com

Send us Fan Mail  What would happen if your clinical trial sites were suddenly banned from using you? In this episode, Darshan Kulkarni uncovers a hidden regulatory shift: state licensing boards are tightening the "Corporate Practice of Medicine" and "Fee Splitting" laws. If your recruitment fees are tied to enrollment or revenue, you aren't just a vendor—you’re a legal liability. We break down the MSO structures that are failing, the "Red Zones" in state law, and how KLF re-architects your contracts to make you the safest, most scalable partner in the life sciences industry.  Support the show www.kulkarnilawfirm.com

Send us Fan Mail  In this tactical masterclass, Darshan Kulkarni breaks down the critical legal architecture required to protect clinical trial sites during rapid expansion. As PIs and Sub-Investigators move between organizations, the risk of losing proprietary data and patient continuity skyrockets. Learn the specific clauses—from non-solicitation to transition requirements—that ensure your site retains its value and your sponsors remain confident. Don't let your most valuable assets walk out the door; learn how to lock down your contracts today.  Support the show www.kulkarnilawfirm.com

Send us Fan Mail  In this episode, Darshan Kulkarni breaks down the staggering legal difference between the branded drugs you know (like Mounjaro) and the compounded versions flooding the market. Using a brilliant "Coke vs. RC Cola" analogy, we explore why "clean vats" aren't the same as "proven science." If you are a patient, a provider, or a legal professional in the life sciences space, you need to understand the four pillars of FDA approval—and why some of the most popular drugs on the market today are legally allowed to skip the hardest parts  Support the show www.kulkarnilawfirm.com

Send us Fan Mail Stop playing compliance theater. In this episode, Darshan Kulkarni pulls back the curtain on a dangerous trend in the life sciences: the over-reliance on contract sales forces without the legal control to back them up. Many companies believe they’ve "solved" the incentive pay problem, only to realize the OIG hasn't changed its mind since 1998. We break down why the "Pikachu face" won't save you when the government comes knocking, the myth of the "basically an employee" legal status, and why your business model might be a walking Anti-Kickback violation. If you’re paying for results but can’t control the behavior, you aren’t scaling—you’re gambling. Support the show www.kulkarnilawfirm.com

Send us Fan Mail  Is AI the savior of clinical research costs, or a ticking time bomb for data integrity? In this episode, Darshan Kulkarni dives into the murky waters of AI-driven sponsor protocols. We explore how AI is being used to mask—and unmask—data falsification, and what life science sponsors must do to ensure compliance before the regulators knock. If you’re using AI to "make life easier," you might be making your legal defense much harder.  Support the show www.kulkarnilawfirm.com

Send us Fan Mail "The model said so" is not a defense. In the rush to integrate AI into drug discovery, life science companies are sprinting toward a compliance cliff. In this episode, Darshan Kulkarni—pharmacist and FDA regulatory lawyer—strips away the marketing hype to reveal the "messy reality" of AI in regulated environments. We dive deep into the three pillars of risk that can sink a biotech firm: Data Integrity: Why AI scales bad data faster than you can fix it.The Ownership Crisis: Why current collaboration agreements aren't ready for probabilistic inventorship.The Accountability Gap: Who does the DOJ point to when the algorithm makes a $500M mistake?If you are an executive or general counsel in the life sciences, this is the briefing you need to hear before your next M&A due diligence or patent filing. Support the show www.kulkarnilawfirm.com

Send us Fan Mail In this episode of DarshanTalks, host and attorney-pharmacist Darshan Kulkarni explores the unsettling transition from "Googling your symptoms" to "Chatting with your symptoms." It’s 10:47 PM—you have chest tightness and a chatbot is your only companion. But is the algorithm reassuring you, or is it gaslighting a medical emergency? We go beyond the hype to examine the February 9, 2026, Nature Medicine study (as reported in the New York Times) which reveals a staggering gap between AI’s medical exam scores and its real-world ability to triage human beings. Darshan breaks down the "Black Box" of emergency room triage, the evolution of FDA Software as a Medical Device (SaMD) regulations, and why your zip code might determine if your data is protected under new 2026 state privacy laws in Washington, California, and Maryland. Key topics include: The "Midnight Triage" Trap: Why AI struggles with the nuance of human shame, fear, and "atypical presentations" in the ER.FDA & the "Glass Box": Navigating the new 2026 guidance on Clinical Decision Support (CDS) software and the legal line between "wellness devices" and "medical devices."Liability & Malpractice: Why an algorithm can’t carry insurance—and what that means for the doctors who follow (or ignore) AI alerts.The Data Privacy Patchwork: How HIPAA fails you once you leave the hospital portal and enter the world of consumer AI chatbots.Healthcare is a human endeavor, and accountability requires a human name. Learn how to use AI as a starting point without letting it be your final conclusion. Support the show www.kulkarnilawfirm.com

Send us Fan Mail  On January 27, 2026, the HHS Office of Inspector General (OIG) changed the game for pharmaceutical manufacturers. In a landmark Special Advisory Bulletin, the government officially opened a "green lane" for direct-to-patient (DTP) drug sales, specifically addressing the rise of cash-pay programs like TrumpRx. In this episode, we break down why the OIG is now prioritizing lower costs over traditional Anti-Kickback Statute (AKS) risks for cash-paying patients—including those on Medicare and Medicaid. If you are a life sciences executive or legal counsel, this is the compliance roadmap you’ve been waiting for.  Support the show www.kulkarnilawfirm.com

Send us Fan Mail The DOJ just changed the rules of the game for the Life Sciences industry. As of January 2025, transferring "Bulk Sensitive Personal Data" to countries of concern—specifically China—is no longer just a compliance hurdle; it’s a potential federal violation. In this episode, Darshan Kulkarni breaks down the six categories of data you must protect immediately, from genomic data to precise geolocation. If you are handling safety data across borders, this is your mandatory executive briefing.  Support the show www.kulkarnilawfirm.com

Send us Fan Mail Is your state "sandbox" a playground or a legal minefield? In this episode, Darshan Kulkarni—pharmacist and attorney—dissects the quiet movement of states like Utah allowing AI to manage and renew prescriptions. While the innovation is exciting, the federal government is watching closely. We break down the three massive risks facing life science companies and healthcare providers today: Clinical Logic Failures: Why a state sandbox can't fix bad AI medicine.The Liability Void: If the AI misses a symptom, who stands in court?The Supremacy Clause: Why state "waivers" don't protect you from the FDA.If you are navigating the intersection of health-tech and regulation, this is the practical take you need to stay compliant and protected. Support the show www.kulkarnilawfirm.com

Send us Fan Mail  The OIG has officially shifted the goalposts for Direct-to-Consumer (DTC) and Direct-to-Patient (DTP) programs. For years, federal healthcare discounts were a "no-go zone," but a new dual-track strategy is emerging—if you know how to build the firewall. In this episode, Darshan Kulkarni breaks down the three core regulatory pillars required to bypass PBM middlemen without triggering federal anti-kickback statutes. We discuss the "one-year commitment" rule, the "seeding" trap, and why your current marketing strategy might be an unintentional red flag for regulators. If you are in Life Sciences commercialization, the "wait and see" approach is now your biggest liability.  Support the show www.kulkarnilawfirm.com

Send us Fan Mail  In this episode of KLF Deep Dive, Darshan Kulkarni uncovers the catastrophic risks clinical trial sites face when they fail to vet their staff against federal exclusion lists. We move beyond simple compliance to discuss the "off-the-books" penalties that can end a career or a company. If you’re in the life sciences, this is the legal shield you can't afford to ignore.  Support the show www.kulkarnilawfirm.com

Send us Fan Mail Undeclared allergens remain the #1 cause of food recalls in the U.S., yet many brands still treat labeling as a "marketing" task rather than a "legal" one. In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the regulatory horror stories of major brands—from Nugo to Frito-Lay—and explains why the FDA doesn't care if your co-manufacturer messed up. If your name is on the bag, you own the risk. Learn how to transition from "marketing font arguments" to FSMA-compliant allergen controls that survive federal scrutiny. Support the show www.kulkarnilawfirm.com

Send us Fan Mail  Think HIPAA is your biggest hurdle in pharma marketing? Think again. In this episode of KLF Deep Dive, Darshan Kulkarni reveals why focusing solely on HIPAA leaves a massive, unregulated gap in your compliance strategy. We break down the "layered system" of risk—from aggressive state privacy laws and medical privacy statutes to the DOJ’s massive 2025 Bulk Data Rule. Whether you’re running patient engagement campaigns or leveraging marketing automation, you’ll learn why the tools you use to scale might be the very tools that trigger a regulatory audit. Don't leave your firm's reputation to a "narrow slice" of engagement.  Support the show www.kulkarnilawfirm.com